Sonoma Biotherapeutics, a clinical-stage biotechnology company developing regulatory T cell therapies, is reducing its workforce with an undisclosed number of employees affected. The company confirmed that roles across all levels and functions would be impacted at locations in South San Francisco, Seattle, and remote positions. The workforce reduction is aimed at right-sizing the organization and extending cash runway through 2027 and potentially into 2028